Pacira BioSciences (PCRX) EBITDA (2010 - 2026)

Pacira BioSciences has reported EBITDA for 17 years, with the latest figure at $4.3 million in Q2 2026.

• On a quarterly basis, EBITDA fell 49.79% year-over-year to $4.3 million in Q2 2026; TTM through Jun 2026 was $19.9 million, a 119.05% increase from a year earlier, with the FY2025 full-year figure at $19.2 million, up 126.16% from the prior year.
• EBITDA was $4.3 million for Q2 2026 at Pacira BioSciences, down from $6.9 million in the prior quarter.
• The five-year high for EBITDA was $39.9 million in Q2 2023, with the low at -$139.5 million in Q3 2024.
• Average EBITDA over 5 years is $5.8 million, with a median of $10.9 million recorded in 2024.
• The largest YoY upside for EBITDA was 527.43% in 2024 against a maximum downside of 887.35% in 2024.
• Over 5 years, EBITDA stood at -$9.9 million in 2022, then soared by 435.27% to $33.2 million in 2023, then retreated by 25.52% to $24.7 million in 2024, then sank by 90.53% to $2.3 million in 2025, then jumped by 82.35% to $4.3 million in 2026.
• The last three EBITDA figures came in at $4.3 million (Q2 2026), $6.9 million (Q1 2026), and $2.3 million (Q4 2025), per Business Quant data.